Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.
about
Akt and mTOR in B Cell Activation and DifferentiationPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)p110γ/δ Double-Deficiency Induces Eosinophilia and IgE Production but Protects from OVA-Induced Airway InflammationSignaling by the phosphoinositide 3-kinase family in immune cellsRole of SHIP-1 in the adaptive immune responses to aeroallergen in the airwaymTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiationImmature B cells preferentially switch to IgE with increased direct Sμ to Sε recombination.PI3Ks in lymphocyte signaling and developmentThe phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic DiseasesImbalanced PTEN and PI3K Signaling Impairs Class Switch Recombination.PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advancesLyn kinase represses mucus hypersecretion by regulating IL-13-induced endoplasmic reticulum stress in asthma.PI3Kδ and primary immunodeficiencies.Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis.Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.Cancer: A targeted treatment with off-target risks.Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches.
P2860
Q21131224-7BCB4CC5-6560-472B-A493-652D8C5D4D8AQ26782633-DE4E6FF8-50EC-4ED7-8C5C-DC274AB4FCE1Q27334428-C0465556-A74C-49C1-A835-67CCE07DCC66Q28283677-30A117C0-A0AF-4601-839B-E2FF56FE1816Q33769016-F9A6F4EF-A572-4E08-9BFE-0A630749ABB5Q34601734-4667633C-CC8E-4986-BC26-266EC6BCD610Q34762309-CE3B2F64-01A0-4170-8C87-E36DB6ADE9C8Q35627706-7865B8A4-74E0-41F8-86F1-2756EB6B0998Q35843746-D60573EA-B2D5-4712-A383-46A68C185A4AQ36150234-8CFFA64C-1BA8-4443-AE55-D100384904B3Q36286414-CB8C565E-9D93-492E-BA15-9DC4A0A26CC0Q36304948-0544DAD2-4F8B-4498-B5E6-4D026832610BQ36516932-1FBD503C-0116-4A62-A110-6BF73447E39DQ37584315-115786CC-1E96-4B4A-A18C-1CF5D8BF6DA9Q37623828-D71ABCA7-3F00-42E2-A24B-1CAD9E1F458DQ37668864-254BE659-EB0D-4C2A-A1A6-7696CEE4872FQ38266869-13318D72-EDAC-408F-A530-15EC35609F6FQ39218787-7EAFA448-1538-492D-A928-CB631224E9C3Q42320922-2AF29B41-2858-4C1D-A0DF-63A09AA33E5AQ46708419-D140AA28-0E7B-4821-9C48-D78E25FD8A66Q48019225-64EB439E-B4A8-4A57-8303-706FBCCCF09A
P2860
Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Genetic or pharmaceutical bloc ...... inase enhances IgE production.
@en
Genetic or pharmaceutical bloc ...... inase enhances IgE production.
@nl
type
label
Genetic or pharmaceutical bloc ...... inase enhances IgE production.
@en
Genetic or pharmaceutical bloc ...... inase enhances IgE production.
@nl
prefLabel
Genetic or pharmaceutical bloc ...... inase enhances IgE production.
@en
Genetic or pharmaceutical bloc ...... inase enhances IgE production.
@nl
P2093
P50
P1476
Genetic or pharmaceutical bloc ...... inase enhances IgE production.
@en
P2093
Baher F Nashed
Bart Vanhaesebroeck
Kamal D Puri
Kevan M Shokat
Ting-Ting Zhang
P304
811-819.e2
P356
10.1016/J.JACI.2008.08.008
P407
P577
2008-10-01T00:00:00Z